|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HOW I TREAT
From the Hematology-Oncology Section, The University of
Oklahoma Health Sciences Center, Oklahoma City, OK.
Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic
syndrome (HUS) are, in adults, clinically and pathologically indistinguishable except for the severity of renal failure. They are
best described as a single disorder, TTP-HUS, because the diagnostic
evaluation and initial management are the same. Treatment with plasma
exchange, available for more than 20 years, has dramatically altered
the course of disease in adults with TTP-HUS. Plasma exchange has
improved survival rates from 10% to between 75% and 92%, creating urgency for the initiation of treatment. This has resulted in decreased
stringency of diagnostic criteria, which in turn has resulted in a
broader spectrum of disorders for which the diagnosis of TTP-HUS is
considered. Long-term follow-up has revealed increasing frequencies of
relapse and of chronic renal failure. Although the increased survival
rate is dramatic and recent advances in understanding the pathogenesis
of these syndromes are remarkable, clinical decisions remain empirical.
Therefore, the management decisions for patients with suspected TTP-HUS
rely on individual experience and opinion, resulting in many different
practice patterns. Multipractice clinical trials are required to define
optimal management.
(Blood. 2000;96:1223-1229) This article, "How I treat patients with
thrombotic thrombocytopenic purpura-hemolytic uremic syndrome,"
is no more than the title states. It is a concise review of the
clinical syndromes, followed by a description of diagnosis and
treatment. There are some observations from published case series that
can guide us, but other than the randomized clinical trial
demonstrating superiority of plasma exchange over plasma
infusion,1 there is no firm evidence on which to base
recommendations. Hence, there are no recommendations here, only
opinions from my experience.
Thrombotic thrombocytopenic purpura (TTP) is a classic disease of
hematology. The onset is often dramatic, as in the initially described
patient,2 and the presenting features, when
characteristic,3 are immediately recognizable. The
defining clinical and pathologic features of TTP were described in a
1966 review3 of 271 patients: thrombocytopenia,
microangiopathic hemolytic anemia, neurologic abnormalities, renal
abnormalities, and fever were present in 88% to 98% of patients; the
pathologic feature of thrombotic microangiopathy was demonstrated in
93% of patients. There was no effective treatment. Ninety percent of
patients died.3 The course of TTP has changed dramatically
since this initial definition.3 With plasma exchange treatment, it has become a curable illness. The availability of effective treatment has created an urgency for establishing the diagnosis, and this urgency has required decreased stringency of
diagnostic criteria, from the classic pentad of clinical
features3 to the current dyad1,4 (Table
1). Inevitably, less stringent diagnostic
criteria have resulted in a broader spectrum of disorders treated
for possible TTP. Long-term follow-up of patients recovered from acute
TTP has revealed an increasing frequency of recurrent episodes5-7 and chronic renal failure.5,7
Hemolytic uremic syndrome (HUS) is a classic disease of nephrology,
initially described as fatal renal cortical necrosis in children.8 It is defined by renal thrombotic
microangiopathy, also the characteristic lesion of TTP,9
and by thrombocytopenia and microangiopathic hemolytic anemia. Its
course also has changed since its initial description, with the
recognition in 1982 of Shiga toxin-producing Escherichia
coli (typically 0157:H7) as a new human pathogen causing epidemic
hemorrhagic colitis.10 These bacteria are now the
predominant etiology of HUS in children10,11 and
occasionally the etiology in adults.12 Children with
epidemic diarrhea-associated HUS are not treated with plasma exchange, and nearly all recover from acute episodes.11 In contrast
to children, adults with TTP-HUS after epidemic E coli
0157:H7 infection have high mortality rates and appear to benefit from
plasma exchange.12
Adults who have the defining diagnostic features of TTP (Table 1) but
in whom acute renal failure is a prominent abnormality, with or without
a diarrhea prodrome, have been described as having adult HUS, and some
consider this as a distinct syndrome. However, the one prospective
study of plasma exchange treatment of TTP-HUS in which patients were
distinguished on the basis of renal failure demonstrated no differences
in other clinical features. The severity of thrombocytopenia and
anemia, and the frequency of focal neurologic signs or symptoms, were
the same in patients with or without acute renal
failure.1,13 This study also reported no difference in
survival rates between patients without (78%)1 or with
(83%)13 acute renal failure.
Yet it has been suggested that patients with HUS are usually
unresponsive to plasma exchange.14 The origin for this
impression is unclear. It may be related to observations that recovery
of renal function is typically slow and often incomplete, in contrast to the recovery of neurologic and hematologic function, or to observations that continued plasma exchange does not seem to benefit persistent renal failure once hematologic recovery has occurred. Or it
may be an extrapolation from experience with
diarrhea-associated HUS in children, who recover without
plasma exchange. However, the published observations12,13
and our experience suggest that patients with acute renal failure
respond to plasma exchange treatment as well as patients without renal
failure, except for the unpredictable recovery of renal function.
Certainly the survival rate of all patients with TTP-HUS, including
patients with acute renal failure, is better than in the era before
plasma exchange.3
This review, focused on evaluation and management in adults, will not
distinguish between TTP and HUS but, rather, will use the term TTP-HUS
to describe all patients. The presence or absence of acute renal
failure may be important for prognosis, but the heterogeneity among
TTP-HUS syndromes in adults is much greater than this single
distinction. Table 2 presents a
classification of TTP-HUS syndromes based on disease associations and
probable etiologies. These adult syndromes are similar regarding
diagnosis and management, despite their different etiologies, disease
associations, and long-term outcomes.
Systemic endothelial cell damage appears to be a central phenomenon in the pathogenesis of all TTP-HUS syndromes. Direct evidence for this are the demonstration of apoptosis of microvascular endothelial cells in spleens removed from patients with TTP15 and the demonstration that plasma from patients with TTP or adult HUS (distinguished from childhood epidemic diarrhea-associated HUS) can cause apoptosis of microvascular endothelial cells.16 Endothelial damage may cause the release of von Willebrand factor (vWF) multimers that are larger than vWF multimers in normal plasma.17 A plasma vWF-cleaving protease has been postulated to decrease the size of large vWF multimers to their normal size in plasma after secretion. Deficiency of this protease has been reported in patients with TTP, but not in patients with HUS (diagnostic criteria for distinguishing TTP from HUS were not reported in this study).18 vWF-cleaving protease deficiency may result in larger plasma vWF multimers that can cause platelet agglutination.19,20 These abnormalities may not be specific for TTP; patients with disseminated malignancies may have unusually large vWF multimers and deficient vWF-cleaving protease activity but no signs of TTP-HUS.21 Other studies have demonstrated enhanced proteolysis of vWF in patients with TTP-HUS, with an accumulation of abnormal low-molecular-weight multimers.22
Oklahoma has a unique opportunity to describe this clinical
syndrome because all patients from our region with clinically suspected
TTP-HUS are treated with plasma exchange by a single institution, the
Oklahoma Blood Institute. The Registry began on January 1, 1989; 211 patients have been treated to the present (April 1, 2000). The number
of patients treated per year has increased from 4 in 1989 to 28 in
1999, consistent with the 7-fold increase between 1981 and 1997 reported by the Canadian Apheresis Group.23 This
remarkable increase may be attributed to the decreased diagnostic stringency described above, with the inclusion of a broader spectrum of
disorders, and to the increased awareness of TTP-HUS. It is important
to emphasize that The Oklahoma TTP-HUS Registry is not a case series of
patients with TTP-HUS but of patients referred for plasma exchange treatment for clinically suspected
TTP-HUS. This distinction is critical. Many patients had
additional diagnoses when plasma exchange treatment for TTP-HUS was
begun, or alternative diagnoses were subsequently discovered. Patients
in whom alternative diagnoses became apparent (Table
3) are probably excluded from most
reported case series, yet on their initial evaluation TTP-HUS was the
primary diagnosis. If these patients had died acutely with no autopsy,
TTP-HUS would have remained the primary diagnosis. Since January 1, 1995, I have participated in the management decisions for 122 (85%) of
143 patients. Follow-up is complete to the current time for 115 of 116 living patients.
In the absence of a gold standard-defining test, the diagnosis of
TTP-HUS rests on the signs and symptoms presented in Table 1. The
primary criteria are thrombocytopenia and microangiopathic hemolytic
anemia. However, some patients may not initially be anemic, though
their hematocrit levels may fall sharply after presentation, and in
some patients red cell fragmentation may not be
apparent.24 Serum lactate dehydrogenase (LDH)
levels are increased, often to very high levels, reflecting not only hemolysis but also diffuse tissue ischemia.25 The absence
of a clinically apparent alternative explanation for these
abnormalities is the critical but difficult component of the diagnosis.
For example, a patient with megaloblastic anemia may, on initial
examination, have mental status changes, thrombocytopenia, and anemia
characterized by many red cell fragments and elevated serum levels of
bilirubin and LDH. If the initial evaluation suggests TTP-HUS but other etiologies are possible, can plasma exchange be withheld? Often it
cannot. Table 3 shows the disorders that may accompany the diagnostic
features of TTP-HUS. Many of these disorders
With the exception of the study demonstrating the superiority of
plasma exchange over plasma infusion1 and a small study demonstrating the equivalence of fresh frozen plasma and
cryosupernatant plasma for the initial treatment plasma,26
there are no randomized clinical trials to provide data for management
decisions. The following observations, then, are based on opinion, not
on evidence. Because syndromes described as TTP or HUS may be
indistinguishable (except for the presence of acute renal failure in
HUS) and both respond to plasma exchange treatment (see above),
vWF-cleaving protease assays cannot be expected to provide therapeutic
guidance. The algorithm for our treatment is presented in Figure
1.
Initial treatment Plasma exchange is the most important treatment.1 The value of additional treatment modalities is unknown. In this report,1 all patients also received aspirin and dipyridamole; none received glucocorticoids. In another case series reported at the same time,27 all patients were treated with glucocorticoids, none with aspirin or dipyridamole. In both reports1,27 clinical outcomes were the same, suggesting that plasma exchange is the critical element of treatment and that neither aspirin, dipyridamole, nor glucocorticoids influenced recovery. Therefore, our practice has been to initiate treatment with only plasma exchange. Plasma exchange is performed once a day and replaces 1 plasma volume with either fresh frozen plasma or cryosupernatant plasma. A theoretical benefit for cryosupernatant plasma has been suggested because it is depleted of von Willebrand factor, and a retrospective survey suggested greater efficacy.28 However, findings from a small, randomized trial suggested equivalent outcomes with both products.26Response to treatment The response to plasma exchange treatment is variable, perhaps reflecting the heterogeneity of TTP-HUS syndromes. Nonfocal neurologic symptoms, such as mental status changes, may resolve immediately and dramatically. Thrombocytopenia typically requires several days for initial recovery to begin. Parameters of hemolysis, such as serum LDH levels, may improve promptly, yet anemia may continue to worsen and further red cell transfusion is often required. Renal failure may also worsen before improvement is noted; recovery from renal failure is unpredictable and often slow, and it may be incomplete.The platelet count seems to be the most important parameter on which to base treatment decisions. Failure of the platelet count to respond requires intensifying treatment. Exacerbation of thrombocytopenia after initial recovery, while the patient continues to receive daily plasma exchanges, signals increased disease activity and necessitates more intense treatment. Recurrent or new neurologic abnormalities may occur during the course of treatment;1 these events are usually predicted by an exacerbation of thrombocytopenia. Often a prompt initial increase of the platelet count is followed by a period of several days with no change, suggesting a diminished response to plasma exchange; in these patients, simply continuing the daily plasma exchange is usually sufficient. If the response to initial treatment is poor, with either no platelet count response or an exacerbation of disease activity during daily plasma exchange, glucocorticoids are added and the volume of plasma exchanged is increased. Glucocorticoid may be oral prednisone (1 mg/kg per day) or higher doses of intravenous methylprednisolone (125 mg twice daily). Plasma exchange may be intensified by increasing the volume of plasma replaced to 1.5 plasma volumes per exchange; our practice is to initiate twice daily exchanges of 1 plasma volume to minimize the recycling of infused plasma. This is a formidable procedure requiring nearly full-time personnel commitment, but refractory patients appear to respond to this plasma dose escalation. Many other modalities have been recommended (splenectomy, aspirin, dipyridamole, vincristine, other immunosuppressive agents, and IVIg), but their efficacy is unclear. The variable clinical course of TTP-HUS makes all anecdotal reports uninterpretable. Persistence and patience with plasma exchange may be the most effective practice. Duration of treatment No clinical parameters predict the required duration for plasma exchange. When remission is established (based on recovery of the platelet count to normal), nonfocal neurologic symptoms are resolved, the hematocrit level is stable but will not yet be normal, the serum LDH value is normal or nearly normal, and renal failure (it is hoped) is beginning to ameliorate. The decision to stop or to continue plasma exchange at this time is empirical. Prompt exacerbation of disease activity, principally manifested by a falling platelet count and requiring the resumption of daily plasma exchange, is common after the discontinuation of plasma exchange treatment, with reported frequencies of 29% to 82%.1,27,29-31 This seems to mandate additional treatment, analogous to "consolidation treatment" used in other disorders. Diminishing the frequency of plasma exchange to several times per week is practical for most patients. The feasibility of continued plasma exchange is often determined by practical, logistical issues such as the safe and efficient function of the central venous catheter or a patient's ability to return for outpatient treatment. Discontinuing plasma exchange treatment is the only way to know whether a durable remission has been achieved, and many cycles of stopping and resuming plasma exchange may be required. The additional modalities described above are often suggested for patients requiring prolonged treatment, but here also persistence with intermittent plasma exchange may be the best way to control disease activity until remission occurs.The response to treatment may be related to the category of clinical presentation (Table 2). Prolonged courses of plasma exchange treatment, with frequent exacerbations when treatment is tapered or stopped, are characteristic of patients with idiopathic TTP-HUS. Patients with TTP-HUS caused by quinine or ticlopidine hypersensitivity, pregnancy, or an enteric infection with bloody diarrhea typically respond promptly and completely. Although the role of plasma exchange treatment in their recovery may be uncertain, in the acute urgency of initial management plasma exchange treatment cannot be withheld. A review of patients with ticlopidine-associated TTP-HUS has demonstrated decreased mortality rates in patients treated with plasma exchange.32 Patients with TTP-HUS caused by dose-related drug toxicity (eg, mitomycin C) or allogeneic marrow transplantation may not benefit from plasma exchange treatment. In contrast to other patients, these patients are often diagnosed and treated after several days of deliberation. Finally, the patient who has a clinically apparent additional diagnosis, such as systemic lupus erythematosus, has an unpredictable course. Management of plasma exchange treatment is often dictated by the activity of the associated condition. Prolonged courses of plasma exchange are uncommon; exacerbations and relapses of presumed TTP-HUS are rare.
Platelet transfusions may be dangerous in patients with TTP-HUS. Patients have been observed to have abrupt, striking deterioration after platelet transfusion, consistent with the exacerbation of thromboses.27 However, we have not observed adverse effects from platelet transfusions when they were required for an invasive procedure. Plasma exchange treatment entails frequent and dangerous risks (Table
4).33 In our prospective
study of 71 consecutive patients treated for clinically suspected
TTP-HUS, 21 (30%) patients had 27 major complications, including 12 systemic infections (1 fatal) and 2 episodes of hemorrhage after
subclavian catheter insertion (1 fatal).33 Other major
complications included pneumothorax, catheter thrombosis requiring
removal of the central venous catheter, venous thrombosis requiring
anticoagulant treatment, hypoxia and hypotension, and serum
sickness.33 Consistent with previous observations,34 hemorrhage with catheter insertion was not
related to the severity of thrombocytopenia; major bleeding did not
occur in 17 patients whose platelet counts were lower than
20 000/µL. Because of the frequency of infections and thrombotic
complications, central venous catheters should be removed as soon as
possible, but this decision is balanced by the estimated risk for
TTP-HUS exacerbation with the requirement for the resumption of plasma exchange.
We have arbitrarily defined a recurrence of disease activity within 30 days of the discontinuation of plasma exchange treatment as an exacerbation of continuing active disease; when TTP-HUS recurs more than 30 days after the last plasma exchange, it is termed a relapse (Figure 1). Several patients have had relapses soon after 30 days, suggesting that this empiric duration may be too short. The variable frequency of reported relapses is dependent on the definitions used, from 2 weeks30 to 6 months6 after the completion of plasma exchange treatment, and on the duration of follow-up, given that relapse may occur after 8 to 10 years of complete remission.6 After the discontinuation of plasma exchange, frequent monitoring of blood counts and LDH values seems important; if these remain normal, the interval between evaluations is quickly extended. Then routine medical care becomes appropriate. One specific precaution we advise is to measure blood counts when symptoms of any systemic illness occur. No maintenance treatment, such as aspirin or intermittent plasma infusions,27 appears to be effective in preventing relapses. Among our patients, the frequency of relapse is different among different categories of TTP-HUS (Table 2).7 Relapses are rare in patients who present during pregnancy or the postpartum period and among patients with an additional or an alternative explanation for their signs and symptoms; relapses are also rare among patients who present with bloody diarrhea; relapses have only occurred among patients with drug-induced TTP-HUS when the drug (quinine) was taken again. Among patients with idiopathic TTP-HUS, the relapse rate has been 20% and the mean follow-up 4.5 years. All patients with relapsed TTP-HUS have responded to plasma exchange treatment. We have rarely attempted to control relapses by splenectomy.35 A dilemma during follow-up is the observation of asymptomatic thrombocytopenia.5 Without knowledge of the patient's history, TTP-HUS would never be suspected, yet asymptomatic thrombocytopenia may be a prodrome for an acute relapse. In some patients retrospective evaluation suggests a long duration of signs and symptoms preceding the initial diagnosis.3,36 These observations challenge the common opinion that TTP-HUS, in contrast to idiopathic thrombocytopenic purpura, is either overtly active or in full remission. As the advent of plasma exchange treatment has created relapsing TTP-HUS, it may also reveal a new spectrum of chronic, smoldering TTP-HUS. The issue is when to intervene because asymptomatic thrombocytopenia itself does not require treatment. Glucocorticoids are simpler and safer than plasma exchange, but they may not be effective; however, the risks associated with central venous catheter insertion and plasma exchange are formidable.33 An issue specific for young women is the risk for future pregnancy. Limited experience suggests that pregnancy is associated with a risk for recurrence but that most subsequent pregnancies are uncomplicated.27
Relapse is not the only concern after successful treatment. Chronic renal failure, defined by a creatinine clearance less than 40 mL/min at 1 year after diagnosis, occurs in one fourth of our patients.7 This is comparable to the experience with children after diarrhea-associated HUS, in whom the frequency of renal function abnormalities and hypertension increases during long-term follow-up.37,38 Some patients report minor but persistent and troublesome problems with fatigue, memory, and concentration. Their significance is unknown. We are documenting and defining these symptoms by annual quality-of-life assessments. Emotional support for patients is another important aspect of management. Coping with a disease unfamiliar to them, their families, and often their primary care physicians can be difficult, and they often have feelings of isolation and vulnerability. These problems led several of our patients to urge me to begin a support group. Although I initially had reservations, we began in 1996, and this has become a well-attended and appreciated occasion 3 times each year. We have also established a series of newsletters to patients and physicians that are distributed throughout our community and are posted on our website (http://moon.ouhsc.edu/jgeorge).
Lack of evidence on which to base recommendations for the care of patients with suspected TTP-HUS affects almost every decision a clinician commonly encounters. Rigorous clinical trial data are required to better define every aspect of diagnosis, treatment, and prognosis. The diagnosis of TTP-HUS is often uncertain, both at the initial episode and sometimes also at relapse, making the decision to initiate plasma exchange treatment difficult. There are no clinical features that help to predict how long plasma exchange treatment may be required. There are no data to support the efficacy of any treatment modality other than plasma exchange. Long-term clinical outcomes, such as chronic renal failure, may be more serious than we realize. Future clinical research must address the following issues: Definition. There is a need to define accurately those patient groups in published case series, using explicit criteria to include and exclude patients, to define acute renal failure when patients are described as having HUS, to document the presence or absence of associated diseases and possible etiologies, and to describe clinical outcomes. Simply identifying patients as having TTP or having HUS is insufficient. Diagnosis. There is a need to develop diagnostic tests and to define clinical features that can be helpful in determining which patients require treatment with plasma exchange and which patients may be safely observed without plasma exchange. Specifically, there is a need to determine the importance of the vWF-cleaving protease activity in diagnostic and management decisions. Treatment. There is a need to develop diagnostic tests and to define clinical features that can predict the optimal duration of plasma exchange treatment. There is a need to determine whether early intervention with any treatment in addition to plasma exchange can improve the rate of initial recovery, decrease the frequency of exacerbations and relapses, and decrease the risk for chronic renal failure. Prognosis. There is a need to describe long-term clinical outcomes of patients after recovery from an acute episode of TTP-HUS, stratified by associated conditions, and to document not only the risk for relapse but also the occurrence of renal failure and hypertension. There is a need to define the risks associated with future pregnancies. It is hoped that with evidence from clinical trials, there will be no need for more opinion-based articles such as this on how to treat patients with TTP-HUS.
I thank my colleague, Sara Vesely, who has organized and analyzed the data of The Oklahoma TTP-HUS Registry and who provides continual critical assessment of clinical opinions. I thank the staff of the Oklahoma Blood Institute and the physicians of Oklahoma City for their support and our patients for their enthusiastic participation in our studies.
Submitted March 3, 2000; accepted April 3, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: James N. George, Hematology-Oncology Section, The University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, OK 73190; e-mail: jim-george{at}ouhsc.edu.
1. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325:93-397.
2.
Moschcowitz E.
An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries.
Arch Intern Med.
1925;36:89-93 3. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45:139-159.
4.
Thompson CE, Damon LE, Ries CA, Linker CA.
Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic.
Blood.
1992;80:1890-1895
5.
Hayward CPM, Sutton DMC, Carter WH Jr, et al.
Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
Arch Intern Med.
1994;154:982-987
6.
Shumak KH, Rock GA, Nair RC, and Canadian Apheresis Group.
Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura.
Ann Intern Med.
1995;122:569-572 7. Vesely SK, George JN, Raskob GE. Long term clinical outcomes of thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome (TTP-HUS) among different patient groups [abstract]. Blood. 1999;94:15a. 8. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hamolytisch-uramische Syndrome: Bilaterale Nierenrindennekrosen bei akuten-erworbenen hamolytischen Anamien. Schweiz Med Woch. 1955;85:905-909. 9. Laszik Z, Silva F. Hemolytic-uremic syndrome, thrombotic thrombocytopenia purpura, and systemic sclerosis (systemic scleroderma) Jennett JC, Olson JL, Schwartz MM, Silva FG eds: Heptinstall's Pathology of the Kidney. Philadelphia: Lippincott-Raven; 1998:1003-1057. 10. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet. 1998;352:1207-1212[Medline] [Order article via Infotrieve]. 11. Siegler RL, Pavia AT, Hansen FL, Christofferson RD, Cook JB. Atypical hemolytic-uremic syndrome: a comparison with postdiarrheal disease. J Pediatr. 1996;128:505-511[Medline] [Order article via Infotrieve]. 12. Dundas S, Murphy J, Soutar RL, et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli 0157:H7 outbreak. Lancet. 1999;354:1327[Medline] [Order article via Infotrieve]. 13. Rock G, Shumak K, Kelton J, et al. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion. 1992;32:710-714[Medline] [Order article via Infotrieve]. 14. Mannucci PM. Thrombotic thrombocytopenic purpura: a simpler diagnosis at last? Thromb Haemost. 1999;82:1380-1381[Medline] [Order article via Infotrieve].
15.
Dang CT, Magid MS, Weksler B, Chadburn A, Laurence J.
Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura.
Blood.
1999;93:1264-1270
16.
Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J.
Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells.
Blood.
1997;89:1224-1234 17. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432-1435[Medline] [Order article via Infotrieve].
18.
Furlan M, Robles R, Galbusera M, et al.
Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
N Engl J Med.
1998;339:1578-1584
19.
Tsai H-M, Lian ECY.
Antibodies to von-Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
N Engl J Med.
1998;339:1585-1594 20. Moake JL, Chow TW. Increased von Willebrand factor (vWf) binding to platelets associated with impaired vWf breakdown in thrombotic thrombocytopenic purpura. J Clin Apheresis. 1998;13:126-132[Medline] [Order article via Infotrieve].
21.
Oleksowicz L, Bhagwati N, DeLeon-Fernandez M.
Deficient activity of vonWillebrand's factor-cleaving protease in patients with disseminated malignancies.
Cancer Res.
1999;59:2244-2250
22.
Galbusera M, Noris M, Rossi C, et al.
Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families.
Blood.
1999;94:610-620
23.
Clark WF, Rock GA, Buskard N, et al.
Therapeutic plasma exchange: an update from the Canadian Apheresis Group.
Ann Intern Med.
1999;131:453-462 24. Fava S, Galizia AC. Thrombotic thrombocytopenic purpura-like syndrome in the absence of schistocytes. Br J Haematol. 1995;89:643-644[Medline] [Order article via Infotrieve]. 25. Cohen JD, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenia purpura. J Clin Apheresis. 1998;13:16-19[Medline] [Order article via Infotrieve]. 26. North American TTP Group, Ziegler Z, Gryn JF, et al. Cryopoor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP) [abstract]. Blood. 1998;92:707a. 27. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. N Engl J Med. 1991;325:398-403[Abstract]. 28. Rock G, Shumak KH, Sutton DMC, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Br J Haematol. 1996;94:383-386[Medline] [Order article via Infotrieve].
29.
Onundarson PT, Rowe JM, Heal JM, Francis CW.
Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura.
Arch Intern Med.
1992;152:791-796 30. Sarode R, Gottschall JL, Aster RH, McFarland JG. Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol. 1997;54:102-107[Medline] [Order article via Infotrieve]. 31. Bandarenko N, Brecher ME, and Members of the US TTP ASG. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apheresis. 1998;13:133-141[Medline] [Order article via Infotrieve].
32.
Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD.
Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention.
Arch Intern Med.
1999;159:2524-2528 33. Rizvi MA, Vesely SK, George JN, et al. Plasma exchange complications in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion. 2000;40:896-901[Medline] [Order article via Infotrieve].
34.
Doerfler ME, Kaufman B, Goldenberg AS.
Central venous catheter placement in patients with disorders of hemostasis.
Chest.
1996;110:185-188
35.
Crowther MA, Heddle N, Hayward CPM, Warkentin T, Kelton JG.
Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura.
Ann Intern Med.
1996;125:294-296 36. Fearing MK, Spar MD, Kahn MJ. Chronic thrombotic thrombocytopenic purpura masquerading as other disease entities. J La State Med Soc. 1998;150:29-31[Medline] [Order article via Infotrieve]. 37. Siegler RL, Milligan MK, Burningham TH, Christofferson RD, Chang S-Y, Jorde LB. Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. J Pediatr. 1991;118:195-200[Medline] [Order article via Infotrieve]. 38. Kelles A, Van Dyck M, Proesmans W. Childhood haemolytic uraemic syndrome: long-term outcome and prognostic features. Eur J Pediatr. 1994;153:38-42[Medline] [Order article via Infotrieve]. 39. Gottschall JL, Neahring B, McFarland JG, Wu G-G, Weitekamp LA, Aster RH. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol. 1994;47:283-289[Medline] [Order article via Infotrieve]. 40. Gordon LI, Kwaan HC. Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost. 1999;25:217-221[Medline] [Order article via Infotrieve]. 41. Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999;55:2457-2466[Medline] [Order article via Infotrieve]. 42. Leach JW, Pham T, Diamandidis D, George JN. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T cell lymphoma (Sezary syndrome): a case report. Am J Hematol. 1999;61:268-270[Medline] [Order article via Infotrieve]. 43. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999;85:2023-2032[Medline] [Order article via Infotrieve]. 44. Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum. 1998;28:1-19[Medline] [Order article via Infotrieve]. 45. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine. 1998;77:195-207[Medline] [Order article via Infotrieve]. 46. Lin Y-C, Chang H-K, Sun C-F, Shih L-Y. Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary origin. South Med J. 1995;88:683-687[Medline] [Order article via Infotrieve]. 47. Brain MC, Dacie JV, Hourihane OB. Microangiopathic hemolytic anemia: the possible role of vascular lesions in pathogenesis. Br J Haematol. 1962;8:358[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. Noris and G. Remuzzi Atypical Hemolytic-Uremic Syndrome N. Engl. J. Med., October 22, 2009; 361(17): 1676 - 1687. [Full Text] [PDF]
|
|
|
|
 |
|
 R Som, R Wynne-Simmons, J Islam, and S Lawman A chicken sandwich leading to intensive care BMJ, February 4, 2009; 338(feb04_2): b200 - b200. [Full Text]
|
|
|
|
 |
|
 B. Lammle, J. A. Kremer Hovinga, and J. N. George Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease Haematologica, February 1, 2008; 93(2): 172 - 177. [Full Text] [PDF]
|
|
|
|
|
|
F. Peyvandi, S. Lavoretano, R. Palla, H. B. Feys, K. Vanhoorelbeke, T. Battaglioli, C. Valsecchi, M. T. Canciani, F. Fabris, S. Zver, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission Haematologica, February 1, 2008; 93(2): 232 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. George Evaluation and Management of Patients With Thrombotic Thrombocytopenic Purpura J Intensive Care Med, March 1, 2007; 22(2): 82 - 91. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Crowther and T. C. Abshire Hemostasis and thrombosis ASH Self-Assessment Program, January 1, 2007; 2007(1): 361 - 407. [Full Text] [PDF]
|
|
|
|
|
|
K. R. McCrae, D. C. Matthews, and M. Linenberger Consultative hematology ASH Self-Assessment Program, January 1, 2007; 2007(1): 466 - 505. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nishi, N. Hanafusa, Y. Kondo, M. Nangaku, Y. Sugawara, M. Makuuchi, E. Noiri, and T. Fujita Clinical Outcome of Thrombotic Microangiopathy after Living-Donor Liver Transplantation Treated with Plasma Exchange Therapy Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 811 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. George Clinical practice. Thrombotic thrombocytopenic purpura. N. Engl. J. Med., May 4, 2006; 354(18): 1927 - 1935. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shibagaki, M. Matsumoto, K. Kokame, S. Ohba, T. Miyata, Y. Fujimura, and T. Fujita Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1289 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Perkins, J. C. Reynolds, T. S. Ahuja, T. Reid, L. Y. Agodoa, E. M. Bohen, C. M. Yuan, and K. C. Abbott Thrombotic microangiopathy in United States long-term dialysis patients Nephrol. Dial. Transplant., January 1, 2006; 21(1): 191 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. J. Hulstein, P. G. de Groot, K. Silence, A. Veyradier, R. Fijnheer, and P. J. Lenting A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B Blood, November 1, 2005; 106(9): 3035 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Galbusera, E. Bresin, M. Noris, S. Gastoldi, D. Belotti, C. Capoferri, E. Daina, P. Perseghin, F. Scheiflinger, F. Fakhouri, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report Blood, August 1, 2005; 106(3): 925 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Levy, D. G. Motto, and D. Ginsburg ADAMTS13 turns 3 Blood, July 1, 2005; 106(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. A. El-Rahman and H. Ammar Cocaine-Induced Acute Hepatitis and Thrombotic Microangiopathy JAMA, June 8, 2005; 293(22): 2715 - 2715. [Full Text] [PDF]
|
|
|
|
|
|
M. L. Linenberger and T. H. Price Use of Cellular and Plasma Apheresis in the Critically Ill Patient: Part II: Clinical Indications and Applications J Intensive Care Med, March 1, 2005; 20(2): 88 - 103. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Kawahara, M. Kanno, M. Matsumoto, S. Nakamura, Y. Fujimura, and S. Ueno Diffuse neurodeficits in intravascular lymphomatosis with ADAMTS13 inhibitor Neurology, November 9, 2004; 63(9): 1731 - 1733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Lee, J.-H. Lee, M.-K. Kim, H. S. Cho, Y. K. Bae, K. H. Cho, S. H. Bae, H. M. Ryoo, K. H. Lee, and M. S. Hyun A Case of Bone Marrow Necrosis with Thrombotic Thrombocytopenic Purpura as a Manifestation of Occult Colon Cancer Jpn. J. Clin. Oncol., August 1, 2004; 34(8): 476 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Espinosa, S Bucciarelli, R Cervera, M Lozano, J-C Reverter, G de la Red, V Gil, M Ingelmo, J Font, and R A Asherson Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies Ann Rheum Dis, June 1, 2004; 63(6): 730 - 736. [Abstract] [Full Text]
|
|
|
|
|
|
C. L. Lau, G. A. Patterson, and S. M. Palmer Critical Care Aspects of Lung Transplantation J Intensive Care Med, March 1, 2004; 19(2): 83 - 104. [Abstract] [PDF]
|
|
|
|
 |
|
 J. E. Sadler, J. L. Moake, T. Miyata, and J. N. George Recent Advances in Thrombotic Thrombocytopenic Purpura Hematology, January 1, 2004; 2004(1): 407 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zheng, K. Nishio, E. M. Majerus, and J. E. Sadler Cleavage of von Willebrand Factor Requires the Spacer Domain of the Metalloprotease ADAMTS13 J. Biol. Chem., August 8, 2003; 278(32): 30136 - 30141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Vesely, J. N. George, B. Lammle, J.-D. Studt, L. Alberio, M. A. El-Harake, and G. E. Raskob ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients Blood, July 1, 2003; 102(1): 60 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. George and S. K. Vesely Thrombotic Thrombocytopenic Purpura: From the Bench to the Bedside, but Not Yet to the Community Ann Intern Med, January 21, 2003; 138(2): 152 - 153. [Full Text] [PDF]
|
|
|
|
|
|
H.-M. Tsai, B. Lammle, V. Bianchi, L. Alberio, M. Furlan, G. Remuzzi, M. Galbusera, and P. M. Mannucci Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura Blood, November 15, 2002; 100(10): 3839 - 3842. [Full Text] [PDF]
|
|
|
|
|
|
B. Plaimauer, K. Zimmermann, D. Volkel, G. Antoine, R. Kerschbaumer, P. Jenab, M. Furlan, H. Gerritsen, B. Lammle, H. P. Schwarz, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13) Blood, November 15, 2002; 100(10): 3626 - 3632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. DeLoughery Thrombocytopenia in Critical Care Patients J Intensive Care Med, November 1, 2002; 17(6): 267 - 282. [Abstract] [PDF]
|
|
|
|
 |
|
 S Ahmed, R K Siddiqui, A K Siddiqui, S A Zaidi, and J Cervia HIV associated thrombotic microangiopathy Postgrad. Med. J., September 1, 2002; 78(923): 520 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Moake Thrombotic Microangiopathies N. Engl. J. Med., August 22, 2002; 347(8): 589 - 600. [Full Text] [PDF]
|
|
|
|
|
|
G. Remuzzi, M. Galbusera, M. Noris, M. T. Canciani, E. Daina, E. Bresin, S. Contaretti, J. Caprioli, S. Gamba, P. Ruggenenti, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome Blood, July 18, 2002; 100(3): 778 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Tostivint, B. Mougenot, A. Flahault, C. Vigneau, M.-A. Costa, J.-P. Haymann, J.-D. Sraer, and E. Rondeau Adult haemolytic and uraemic syndrome: causes and prognostic factors in the last decade Nephrol. Dial. Transplant., July 1, 2002; 17(7): 1228 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bianchi, R. Robles, L. Alberio, M. Furlan, and B. Lammle Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura Blood, June 28, 2002; 100(2): 710 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Y. Au, S. C. Tang, K. W. Chan, K. K. Wong, and C. G. C. Ooi Pulmonary Renal Syndrome and Thrombotic Thrombocytopenic Purpura in a Patient With Giant Cavernous Hemangioma of the Leg Arch Intern Med, January 28, 2002; 162(2): 221 - 222. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Chakinala, M. H. Kollef, and E. P. Trulock Critical Care Aspects of Lung Transplant Patients J Intensive Care Med, January 1, 2002; 17(1): 8 - 33. [Abstract] [PDF]
|
|
|
|
|
|
J. N. George, J. E. Sadler, and B. Lammle Platelets: Thrombotic Thrombocytopenic Purpura Hematology, January 1, 2002; 2002(1): 315 - 334. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kojouri, S. K. Vesely, and J. N. George Quinine-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome: Frequency, Clinical Features, and Long-Term Outcomes Ann Intern Med, December 18, 2001; 135(12): 1047 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Veyradier, B. Obert, A. Houllier, D. Meyer, and J.-P. Girma Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases Blood, September 15, 2001; 98(6): 1765 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. McCrae, J. B. Bussel, P. M. Mannucci, G. Remuzzi, and D. B. Cines Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders Hematology, January 1, 2001; 2001(1): 282 - 305. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
such as preeclampsia,
autoimmune disorders, and malignant hypertension